Penalty Amount
$7,500,000
Texas Attorney General Ken Paxton announced a $7.5 million settlement with Tris Pharmaceuticals over alleged misrepresentations about the efficacy of Dyanavel XR, an ADHD drug marketed for children. The release says the company overstated the drug’s efficacy and directed sales representatives to make misleading claims to doctors, including Medicaid providers.
Tris Pharma is required to pay $7.5 million to Texas. No other remedies are specified in the press release.
Review pharmaceutical marketing, distribution, and sales-representative agreements for requirements that efficacy and comparative claims be supported by reliable evidence, approved before use, and consistent across sales calls and materials. Add or strengthen obligations for representative training, monitoring, recordkeeping, and cooperation with investigations, together with audit rights and indemnification for false or unsupported claims. For customer and healthcare-provider agreements, check that product representations and Medicaid-related certifications are accurate and appropriately limited; this release does not describe a privacy violation.
Entity
Tris Pharmaceuticals
Industry
HealthcareOfficial Press Release
https://www.texasattorneygeneral.gov/news/releases/attorney-general-paxton-secures-75-million-settlement-tris-pharma-misrepresenting-efficacy-adhd-drug
Executed Settlement
https://www.texasattorneygeneral.gov/sites/default/files/images/press/Executed%20Settlement.pdf
Texas Attorney General Enforcement Page
https://www.texasattorneygeneral.gov/consumer-protection/privacy
"Tris Pharmaceuticals (“Tris Pharma”)"
"requiring Tris Pharma to pay $7.5 million to Texas."
"Tris Pharma overstated the drug’s efficacy and directed sales representatives to make misleading claims to doctors, including Texas Medicaid providers, that Dyanavel XR worked significantly faster than competing drugs and provided other unproven benefits to pediatric patients."
"October 01, 2026 | Press Release"
$3.0M
Texas Attorney General Ken Paxton announced a settlement requiring Temu to protect Texans’ sensitive personal data from exposure to the Chinese Communist Party and to strengthen product-safety practices. Temu must pay Texas $3 million, comply with data-security requirements backed by a potential $8 million annual penalty, conduct annual independent product testing, and take specified action on products found to contain harmful substances.
$773.0M
Texas Attorney General Ken Paxton announced that a multistate coalition had secured an opioid settlement with Albertsons, which would require the grocery chain to pay more than $773 million nationally once final. Texas and its political subdivisions may receive up to $57.8 million for opioid abatement; the release does not identify privacy violations.
Texas Attorney General Ken Paxton sued Gerber Products Company and Nestlé USA, Inc., alleging that Gerber made deceptive safety and testing claims while its baby food contained dangerous levels of toxic heavy metals. The lawsuit asserts claims under the Texas Deceptive Trade Practices Act; the release does not report a settlement, monetary penalty, or court order.
$1.5M
The Texas Attorney General obtained a judgment holding Rubinsky Roofing LLC liable for 27 violations of the Texas Deceptive Trade Practices Act, including deceptive practices involving older consumers and payment for unnecessary or unfinished repairs. The judgment requires more than $1.5 million in civil penalties, allocates at least $500,000 to consumer restitution, and permanently bars the company and its owner from the practices at issue.
The Texas Attorney General opened an investigation into UnitedHealth Group over allegations that its insurance-benefit administration and patient-care decisions denied Texans medically necessary healthcare. The AG issued Civil Investigative Demands to collect evidence; the release announces no penalty or remedy.
Texas Attorney General Ken Paxton announced an agreement with Plum Organics requiring stronger testing and limits for heavy metals in covered baby food products, along with publicly accessible testing results. The release does not state a monetary penalty; the agreement follows an ongoing investigation into baby food manufacturers.